{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T08:08:30Z","timestamp":1743926910240},"reference-count":15,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>In 2016, the Centers for Medicare and Medicaid Services cut payments for robotic prostatectomy performed for Medicare beneficiaries. Although regulations mandate that billing for urethral suspension is only acceptable for preexisting urinary incontinence, reductions in reimbursement may incentivize billing for the use of this procedure in other scenarios.<\/jats:p><\/jats:sec>Objective<\/jats:title>To assess trends and geographic variations in payments for urethral suspension with robotic prostatectomy in the context of Medicare payment policy.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This US population-based retrospective cohort study analyzed data from the IBM MarketScan Commercial Claims and Encounters and Medicare Supplemental Database for men with employer-based insurance (primary commercial or Medicare supplemental coverage) who underwent robotic prostatectomy (Current Procedural Terminology<\/jats:italic> [CPT<\/jats:italic>] code 55866) between 2009 and 2019.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Time period and metropolitan statistical area of patient residence.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Payment for urethral suspension (CPT<\/jats:italic> code 51990) with robotic prostatectomy.<\/jats:p><\/jats:sec>Results<\/jats:title>We identified 87\u202f774 men with prostate cancer treated with robotic prostatectomy; 3352 (3.8%) had undergone urethral suspension. The mean (SD) patient age was 59.7 (6.5) years; 16\u202f870 patients (19.2%) had Medicare supplemental coverage. From 2015 to 2016, median payments for robotic prostatectomy changed by \u2212$358 (\u221217.0%) for Medicare beneficiaries vs \u2212$9 (0%) for commercially insured patients. With urethral suspension vs without, median (IQR) episode payments for robotic prostatectomy were higher for commercially insured men ($3678 [$3090-$4503] vs $3322 [$2601-$4306]) and Medicare beneficiaries ($2927 [$2450-$3909] vs $2379 [$2014-$3512]). Compared with men treated between 2013 and 2015, those treated between 2016 and 2017 were twice as likely to undergo urethral suspension (8.5% vs 4.1%; odds ratio, 2.17 [95% CI, 1.96-2.38]). The proportion of patients who underwent urethral suspension was stable for 2018 to 2019 and 2016 to 2017 (8.5% vs 9.0%; odds ratio, 1.06 [95% CI, 0.96-1.18]). From 2015 to 2019, the proportion of patients who underwent urethral suspension was highest in Charleston, South Carolina (92.0%), Knoxville, Tennessee (66.0%), and Columbia, South Carolina (58.0%). These regions neighbored high-volume areas without patients who underwent prostatectomy with urethral suspension (eg, 146 patients in Greenville, South Carolina, and 173 in Nashville, Tennessee).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this study, urethral suspension was associated with increased costs for patients with both commercial insurance and Medicare. Patients treated between 2016 and 2017 were more likely than those treated between 2013 and 2015 to undergo this procedure. Geographic variation in use exceeded what was expected for the preexisting condition for which billing is permitted for Medicare beneficiaries. Policy statements from professional societies highlighting appropriate billing for urethral suspension may have tempered, but not reversed, the broad adoption of this procedure.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2022.33636","type":"journal-article","created":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T15:01:44Z","timestamp":1664895704000},"page":"e2233636","source":"Crossref","is-referenced-by-count":2,"title":["Trends in Urethral Suspension With Robotic Prostatectomy Procedures Following Medicare Payment Policy Changes"],"prefix":"10.1001","volume":"5","author":[{"given":"Jonathan","family":"Li","sequence":"first","affiliation":[{"name":"Department of Urology, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dattatraya","family":"Patil","sequence":"additional","affiliation":[{"name":"Department of Urology, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin J.","family":"Davies","sequence":"additional","affiliation":[{"name":"University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania"},{"name":"Department of Urology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher P.","family":"Filson","sequence":"additional","affiliation":[{"name":"Department of Urology, Emory University School of Medicine, Atlanta, Georgia"},{"name":"Winship Cancer Institute, Emory Healthcare, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","published-online":{"date-parts":[[2022,10,4]]},"reference":[{"issue":"19","key":"zoi220956r1","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1056\/NEJMsa0910784","article-title":"Reimbursement policy and androgen-deprivation therapy for prostate cancer.","volume":"363","author":"Shahinian","year":"2010","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi220956r2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv331","article-title":"Doing more for more: unintended consequences of financial incentives for oncology specialty care.","volume":"108","author":"O\u2019Neil","year":"2015","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"zoi220956r3","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1111\/hesr.v56.4","article-title":"Medicare fee reductions and the overuse of intensity-modulated radiotherapy.","volume":"56","author":"Howard","year":"2021","journal-title":"Health Serv Res"},{"issue":"4","key":"zoi220956r4","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1089\/end.2010.0413","article-title":"The impact of anterior urethropexy during robotic prostatectomy on urinary and sexual outcomes.","volume":"25","author":"Johnson","year":"2011","journal-title":"J Endourol"},{"issue":"6","key":"zoi220956r5","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1111\/bju.2012.110.issue-6","article-title":"Anterior suspension combined with posterior reconstruction during robot-assisted laparoscopic prostatectomy improves early return of urinary continence: a prospective randomized multicentre trial.","volume":"110","author":"Hurtes","year":"2012","journal-title":"BJU Int"},{"issue":"3","key":"zoi220956r7","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1023\/A:1020436509217","article-title":"Spillover effects of Medicare fee reductions: evidence from ophthalmology.","volume":"2","author":"Mitchell","year":"2002","journal-title":"Int J Health Care Finance Econ"},{"issue":"5","key":"zoi220956r8","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1002\/cncr.v116:5","article-title":"The effect of changes in Medicare reimbursement on the practice of office and hospital-based endoscopic surgery for bladder cancer.","volume":"116","author":"Hemani","year":"2010","journal-title":"Cancer"},{"issue":"1","key":"zoi220956r9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s10552-016-0835-1","article-title":"Mammography rates after the 2009 revision to the United States Preventive Services Task Force breast cancer screening recommendation.","volume":"28","author":"Qin","year":"2017","journal-title":"Cancer Causes Control"},{"issue":"1","key":"zoi220956r10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1001\/jamaoncol.2021.5143","article-title":"Changes in prostate-specific antigen testing relative to the revised US Preventive Services Task Force recommendation on prostate cancer screening.","volume":"8","author":"Leapman","year":"2022","journal-title":"JAMA Oncol"},{"issue":"13","key":"zoi220956r11","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1002\/cncr.31337","article-title":"PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening.","volume":"124","author":"Kearns","year":"2018","journal-title":"Cancer"},{"issue":"1","key":"zoi220956r12","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/JU.0000000000002176","article-title":"Prospective multicenter comparison of open and robotic radical prostatectomy: the PROST-QA\/RP2 consortium.","volume":"207","author":"Chang","year":"2022","journal-title":"J Urol"},{"issue":"10","key":"zoi220956r13","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.28646","article-title":"Adoption of new risk stratification technologies within US hospital referral regions and association with prostate cancer management.","volume":"4","author":"Leapman","year":"2021","journal-title":"JAMA Netw Open"},{"key":"zoi220956r14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.644885","article-title":"Variation in the use of active surveillance for low-risk prostate cancer across US census regions.","volume":"11","author":"Al Hussein Al Awamlh","year":"2021","journal-title":"Front Oncol"},{"issue":"1","key":"zoi220956r15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/SLA.0000000000003165","article-title":"Understanding the costs associated with surgical care delivery in the Medicare population.","volume":"271","author":"Kaye","year":"2020","journal-title":"Ann Surg"},{"key":"zoi220956r6","unstructured":"American Urological Association. Can you bill a urethral suspension with radical prostatectomy? 2017. Accessed March 7, 2022. https:\/\/www.urologytimes.com\/view\/can-you-bill-urethral-suspension-radical-prostatectomy"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2797028\/li_2022_oi_220956_1664302667.89162.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T15:01:48Z","timestamp":1664895708000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2797028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,4]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.33636","relation":{},"ISSN":["2574-3805"],"issn-type":[{"type":"electronic","value":"2574-3805"}],"subject":[],"published":{"date-parts":[[2022,10,4]]}}}